Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MRCP PACES Consultations (History, Miscellaneous) > Scleroderma (Morphea, Systemic Sclerosis) > Flashcards

Scleroderma (Morphea, Systemic Sclerosis) Flashcards

You may prefer our related Brainscape-certified flashcards:
AP® U.S. History flashcards European History 101 flashcards AP® European History flashcards AP® World History flashcards World History 102 flashcards U.S. History 102 flashcards World History 101 flashcards U.S. History 101 flashcards
1
Q

Scleroderma is a rare and devastating systemic autoimmune disease characterised by __ and __.
As the name suggest: sclero (thick), derma (skin)

Almost all patients with scleroderma have (3)

A

Organ fibrosis, vasculopathy

Skin thickening
Raynaud’s phenomenon
Oesophageal dysmotility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Scleroderma dance

A

A. Inspection
1. Sclerotic skin over face, fingers
- Smooth, shiny, tight
2. Loss of facial wrinkles
3. Perioral puckering, restricted mouth opening
4. Pinched nose
5. Telangiectasia of face, arms
6. Sclerodactyly and flexion deformities
7. Dilated nailfold capillaries and gangrene
8. Raynaud’s phenomenon
9. Palpable calcinosis

  1. Others - oedema, livedo reticularis, morphoea, pigmentation, scarring alopecia, vitiligo

B. Look for mixed connective tissue disease
- RA, SLE, polymyositis

C. Complications
1. Interstitial lung disease
2. Pulmonary hypertension
3. Restrictive cardiomyopathy
4. Primary biliary cirrhosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the organ systems involved in SSc

A

A. Skin

B. Musculoskeletal
1. Arthritis
2. Myositis and myopathy
3. Intra-articular calcification
4. Osteopenia

C. Gastrointestinal
1. Oesophagus dysmotility - dysphasia, GERD
2. Intestinal dysmotility - SIBO, steatorrhoea, malabsorption
3. Pneumatosis coli
4. Colonic diverticular disease
5. Bowel obstruction
6. Primary biliary cirrhosis

D. Renal
1. Malignant hypertension
2. Glomerulonephritis
3. Scleroderma renal crisis (SRC)

E. Respiratory
1. Interstitial lung disease - restrictive pattern
2. Pleural effusion
3. Atelectasis

F. Cardiovascular
1. Restrictive cardiomyopathy (myocardial fibrosis)
2. Pericarditis
3. Pericardial effusions
4. Pulmonary hypertension
5. Conduction defects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Outline the management of SSc

A

General
1. Patient education and counseling
2. Multidisciplinary team approach - Rheumatology, Cardiology, Respiratory, Gastrointestinal, Renal
3. PT OT - contractures, deformity
4. Analgesia for arthritis/arthralgia

Raynaud’s phenomenon
1. Smoking cessation
2. Hand warmers
3. Vasodilators - CCB, ACEi, prostacyclin analogues
4. Sympathectomy in severe cases

Gastrointestinal
1. Low residual diet, nutritional supplement
2. Antibiotics for SIBO
3. PPI and prokinetics for reflux and dysmotility

Renal
1. Aggressive management of hypertension
2. ACE inhibitor for renal crisis

Respiratory
1. Vasodilators for pulmonary hypertension
2. Anti-fibrotic for pulmonary fibrosis (D-penicillamine, interferon gamma)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Classification of scleroderma

A

A. Localised scleroderma - dermal fibrosis without internal organ involvement
1. Morphea - single/multiple plaques on trunk

  1. Linear scleroderma - bands of skin thickening on legs or arms, face (en coup de sabre)

B. Generalised scleroderma (SSc)
1. Limited cutaneous SSc (LcSSc)
- Skin thickening over neck/face, distal to elbows/knees
- Raynaud’s, GERD, telangiectasis, calcinosis, sclerodactyly
- Late involvement of organs, rarely renal crisis
- May still develop life threatening disease
- May progress with development of antibodies
> Anti-topoisomerase (anti-Scl-70): ILD
> Anti-centromere (ACA): PAH

  1. Diffuse scleroderma (DcSSc)
    - Skin thickening proximal to elbows/knees, truncal involvement
    - Abrupt, rapid and early presentation/involvement
    - RNA polymerase III antibody: renal crisis
  2. Systemic sclerosis sine scleroderma (ssSSc)
    - Internal manifestation of SSc + antibody, WITHOUT skin thickening
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Natural progression of centromere positive LcSSc

A

Longstanding Raynauds
5-10 years - sclerodactyly, GERD, telangiectasia, calcinosis, ILD
10-20 years - PAH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Natural progression of DcSSc

A

Within a year - skin features, CREST
(more rapid in Scl-70, RNA pol III)
1-5 years - renal crisis, severe ILD
> 5 years - PAH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is CREST

A

C: Calcinosis
R: Raynaud’s phenomenon
E: Esophageal dysmotility
S: Sclerodactyly
T: Telangiectasis

  • Outdated term and mislead impression into thinking it is an exclusive category of SSc
    (In fact, LcSSc and dcSSc can both have some or all of these features)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why does scleroderma classification matter?

A

Different phenotypes progresses differently, coupled with specific autoantibodies and internal organ manifestation

  • LcSSc + ACA: high PAH, rarely ILD/SRC
  • LcSSc + anti-Scl-70: high ILD, rarely SRC
  • DcSSc + RNA-pol3: high SRC
  • RNA-pol3: malignancy (necessitating age appropriate screen)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ACR/EULAR Classification Criteria for SSc

A
  1. Skin thickening of bilateral fingers proximal to MCPJ
  2. Skin thickening of fingers - puffy fingers, whole fingers distal to MCP
  3. Fingertip lesions - digital tip ulcers, pitting scars
  4. Telangiectasia
  5. Abnormal nailfold capillaries
  6. PAH and/or ILD
  7. Raynaud’s phenomenon
  8. Scleroderma-related antibodies

Interpretation: 9 points or more - definite SSc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Challenges in classifying limited vs diffuse scleroderma

A

Both limited and diffuse scleroderma may manifest similar organ system involvement, but differing percentage

Both
Skin thickening
Raynaud’s phenomenon
Arthralgia
Oesophageal dysmotility
Pulmonary fibrosis

More in limited
Telangiectasia
Calcinosis

More in diffuse
Tendon friction rub
Myopathy
Congestive heart failure
Renal crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Epidemiology of SSc

A
  1. Women > men (4:1)
  2. Younger age
  3. African Americans, native Americans
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pathophysiology of SSc

A

Unknown, but postulated

Complex interaction of genetics, sex, external triggers (silica dust)

Endothelial disruption
Platelet activation
Fibroblast proliferation
Fetal microchimerism
Increased transforming growth factor (TGF-B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Main cause of mortality in SSc

A

Currently:
1. ILD (35%)
2. PAH (26%)
3. Cardiomyopathy (26%) - heart failure, arrhythmias
4. Infections (33%)
5. Malignancy (31%)

Previously scleroderma renal crisis (now 4%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pathophysiology of skin changes in SSc

A
  1. Excessive production of collagen, accumulation of GAG and fibronectin in extracellular matrix (by fibroblasts)
  2. Loss of sweat glands, hair loss in areas of tight skin
  3. Begins on the fingers and hands in almost all SSc
    (If it begins elsewhere - morphea, eosinophilic fasciitis, scleroderma mimic should be considered)
  4. Skin disease/progression/severity does not necessarily predict internal organ involvement.
    - SSc categories and antibodies predict internal organ involvement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Modified Rodnan Skin Score (mRSS)

A

17 areas on the body, each graded 0 to 3
Total possible score of 51

Score over 15-20 and rapid progression within 1st year indicate severe skin thickening

Most skin without therapy softens or atrophies over 3-10 years

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How would you manage skin thickening in SSc?

A

Acute phase - itch reduction
1. Low dose prednisolone 15mg/day
2. Benzodiazepine - pruritus
3. Gabapentin or pregabalin
4. Topical emollients
5. Avoid scratching
6. Emerging - naltrexone

Therapeutics
1. Mycophenolate mofetil (MMF)
2. Methotrexate
3. Cyclophosphamide
4. IVIG 2g/kg per month

Emerging immunomodulators
1. Tocilizumab, abatacept
2. Haematopoietic stem cell transplantation (HSCT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is Raynaud’s phenomenon?

A

Self-limiting, reversible vasomotor disturbance of distal circulation (fingers, toes, ears, nose, tongue, lips) in response to cold, stress or spontaneously

Colour change: Pallor (white) -> cyanosis (blue) -> erythema (red)
Symptoms: numbness, tingling, pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What features in combination with Raynaud’s phenomenon would suggest early SSc?

A
  1. Positive SSc-specific antibodies
  2. Nailfold capillary abnormalities (drop out or dilatation)
  3. Tendon friction rubs
  4. Digital oedema/puffy hands
  5. Digital infarct/ulceration
  6. Oesophageal hypomotility (dilated oesophagus)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Describe the nailfold capillary changes and progression in SSc

A

Early: few giant capillaries, microhaemorrhages. No loss of capillaries, preserved distribution

Active: frequent giant capillaries and microhaemorrhages, moderate loss, mild disorganisation of architecture

Late: ABSENT giant capillaries and microhaemorrhages, severe losses. Ramification due to neoangiogenesis and disorganised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Cardiopulmonary testing in SSc

A
  1. HRCT thorax
  2. Lung function test (ILD) and DLco (PAH)
  3. Echocardiogram
  4. 6 minute walk test (6MWT)
  5. ECG +/- Holter
  6. NT-proBNP - surrogate

Rationality: complications of ILD, PAH, cardiomyopathy and arrhythmias

22
Q

What are the commonest ILD pattern in SSc?

A
  1. Non-specific interstitial pneumonia (NSIP)
  2. Usual interstitial pneumonia (UIP)
23
Q

Which SSc are at high risk of progressive ILD?

A
  1. Positive anti-SCl-70
  2. dcSSc
  3. Isolated nucleolar staining ANA
24
Q

How are cardiopulmonary testings useful in SSc evaluation

When should we treat SSc-ILD?

Prognosis of SSc-ILD

A

Serial lung function test - FVC, DLco quantifies ventilatory capacity and gas exchange, clues on PAH

More robust response of cyclophosphamide in progressive ILD
- Decline > 10% predicted FVC
- Decline > 15% predicted DLco
- HRCT involving > 20-50% of lung

Prognosis
FVC < 70%, 5-year survival 60-65%
HRCT > 20% involvement, 5-year survival 60%

25
Q

Should a patient with SSc-ILD undergo lung biopsy?

A

Typically not required, studies shown no impact in prognosis if HRCT consistent with NSIP or UIP

Indicated if:
1. Atypical pattern on CT scan
2. Alternative explanation for ILD (hypersensitive pneumonitis)

26
Q

Therapeutic options for SSc-ILD

A

(Scleroderma Lung Studies I and II, Fibrosing Alveolitis Trial)
1. Cyclophosphamide
2. MMF (safer, better tolerated)

Refractory
1. Rituximab
2. Azathioprine
3. CNI - cyclosporin, tacrolimus
4. Autologous HSCT

Novel immunomodulators
1. Pirfenidone
2. Nintedanib

27
Q

Autologous stem cell transplant (HSCT) in SSc

A

ASTIS trial
- Improved event-free survival, reduced mortality over 6 years
- Clinical improvement in both subjective and objective outcomes at 2 years
- However, increased mortality 1st year: 10.1%
- However, increased adverse effect 1st 2 years

SCOT trial
- Event-free survival at 5 years in 79% HSCT vs 50% cyclophosphamide
- However, mortality 3-6% HSCT vs 0% in cyclophosphamide

Recommendations:
1. Consider in early dcSSc with mild-mod internal organ involvement (within 5 years onset) AND
2. Failed immunosuppression (not improving or worsening)
3. Exclude active smokers
4. Exclude cardiopulmonary involvement

28
Q

Prevalence of SSc-PH
Classification of pulmonary hypertension

A

Prevalence of SSc-PH: 10-15%

Classification of pulmoanry hypertension
Group 1: PAH
Group 2: PH with left heart disease
Group 3: PH with chronic hypoxia (ILD)
Group 4: Chronic thromboembolism
Group 5: Unclear or multifactorial (sarcoidosis)

29
Q

What are the commonest SSc-PH?
Why is it important to classify it?
Diagnostic assessment of SSc-PAH

A

Commonest: group 1 (PAH)
Others: group 2 (left heart) and 3 (ILD)

However, SSc-PAH therapies are approved only for group 1

Diagnosis of SSc-PAH (group 1)
1. Right heart catheterisation
- PASP > 25mmHg
- PCWP < 15mmHg
- Pulmonary vascular resistance > 3 Wood units
(left heart disease PH - PCWP > 15mmHg)

30
Q

Clinical features of PAH

A
  1. Dyspnoea
  2. Fatigue
  3. Right heart failure - lower limb oedema, TR, elevated JVP, hepatomegaly, RV heave
  4. DLco reducing < 60%
  5. TTE findings of right heart failure
  6. Adjuncts: elevated BNP
31
Q

Risk factors for SSc-PAH

A
  1. LcSSc (longstanding)
  2. Long duration of Raynaud’s
  3. ACA or isolated nucleolar pattern ANA
  4. Extensive telangiectasia
  5. DLco < 60% in absent of extensive ILD or other causes (emphysema)
  6. FVC/DLco ratio > 1.6
32
Q

Management of PAH

A
  1. Calcium channel blockers
  2. Fluid restriction and diuretics, low salt diet
  3. Supplemental oxygen
  4. Controversial for warfarin (increased bleeding risk with unclear benefit in SSc)

Specific therapies
1. Prostacyclins (inhaled iloprost or PO trepostinil)
2. Endothelin receptor antagonist (bonsentan, ambrisentan, macitentan)
3. NO potentiator/PDE5i (sildenafil, tadalafil)
4. gyanylate cyclase simulator (riociguat)

AMBITION trial - ambrisentan + tadalafil shown lesser clinical deterioration than monotherapy

33
Q

SSc related cardiac complications

A
  1. Conduction system disease
  2. Diastolic dysfunction and group 2 PHT
  3. Cardiomyoparhy
  4. Pericardial effusion
  5. Pericarditis
  6. Coronary artery disease
34
Q

Scleroderma renal crisis

A

Commonly hypertensive acute renal failure
Less commonly normotensive renal failure

Highest risk in patients with early diffuse skin thickening and RNA polymerase III antibody

Presentation
1. Arterial hypertension (>150/90)
2. Retinopathy
- Grade 3 flame shaped haemorrhage/cotton wool exudates
- Grade 4 papilloedema
3. Rapid deterioration in renal function (within a month)
4. Pericardial effusion

Prognosis - 50% requires dialysis; 20-40% mortality (5-year)
(among them, half achieve improved renal function with ACEi)

35
Q

Abnormal laboratory tests in SRC

A
  1. RP: Rapidly deteriorating renal function test
  2. UFEME/dipstick: proteinuria
  3. FBC: Consumptive thrombocytopenia, anaemia
  4. PBF: Microangiopathic haemolysis (schistocytes)
  5. Elevated renin level (x2 upper limit)
  6. ADAMTS13 normal or slight reduced
36
Q

Mimics to SRC

A
  1. TTP/HUS
    - ADAMTS13 significantly reduced
  2. ANCA-associated glomerulonephritis
    - Can occur concurrently with SSc, but not due to SRC
    - No haemolysis
    - Lesser degree of hypertension
    - UFEME: RBC casts present
    - ANCA antibody positive
    - Renal biopsy - ANCA vasculitis
37
Q

Risk factors for SRC

A
  1. Early diffuse scleroderma
  2. Tendon friction rub
  3. Corticosteroids or cyclosporin use
  4. Anti-RNA polymerase III antibody
38
Q

Poor prognostic factors for SRC

A
  1. Male
  2. Initial creatinine > 265 umol/L
  3. Normotensive SRC
  4. Cardiac involvement - arrhythmia, myocarditis
39
Q

Treatment and management of SRC

A

A. Hypertensive control
1. Short acting ACE inhibitor - captopril, enalapril (ARBs are not effective!)
- Target reduction 20mmHg within 24 hours
- Avoid hypotension
- Avoid use as prophylaxis - worse prognosis

  1. Second line: CCB, ARB

B. Renal replacement therapy
1. Dialysis
- 50% patients require dialysis in first 24 months
- ACE inhibitors continued indefinitely even in ESRF on haemodialysis

  1. Kidney transplant
    - Delayed at least 24 months
40
Q

Gastrointestinal manifestation of SSc

A

Upper GI tract: oesophagus dysmotility
- GERD, dysphagia, nausea
- Stricture
- Barrett’s oesophagus (10-15%)
- Gastric antral vascular ectasia (GAVE)
- Aspiration and cough

Lower GI tract
- Hypomotility, bloating, nausea
- SIBO - fluctuating constipation/diarrhoea
- Malabsorption
- Pseudo-obstruction
- Pneumatosis coli
- Loss of rectal sphincter tone - fecal incontinence
- Rectal prolapse

41
Q

Pathophysiologic progression of GI involvement in SSc

A
  1. Neural dysfunction - arteriolar changes of vasa nervorum -> dysmotility
  2. Smooth muscle atrophy
  3. Smooth muscle fibrosis
42
Q

Assessment of GI motility in SSc

A
  1. Manometry
  2. Barium oesophagogram
  3. Barium swallow
  4. CT abdomen and pelvis
  5. OGD and colonoscopy
43
Q

Management of oesophageal dysmotility

A

As per GERD

Non-pharmacological
1. Head elevation
2. Fixed mealtime, away from bedtime

Pharmacological
1. Prokinetics: metoclopramide, erythromycin, domperidone (only in early stages - late stage fibrosis renders ineffectiveness)
2. Acid reduction - antacids, H2 antagonist, PPI
3. Refractory: octreotide, botox injection
4. Surgical fundoplication

44
Q

Management of SIBO in SSc

A
  1. Choice of antibiotics
    - Rifaximin 550mg TDS
    - Ciprofloxacin 500mg BD
    - Augmentin 625mg BD
    - Metronidazole 400mg TDS
  2. Avoid loperamide
  3. Vitamins, minerals supplement, FODMAP
  4. Sacral nerve stimulation for fecal incontinence
45
Q

Calcinosis is __ of calcium phosphate over the __, __ and __. (can also occur anywhere on the body)

Deposits are firm, irregular and non-tender, size __. They can be __, __ or __with __ discharge.

A

Cutaneous deposition
Hands (PIPJ, fingertips), periarticular tissues, bony prominences (elbows, knee extensors)

Size of 1mm to several cm
Inflamed, infected, ulcerated, chalky white material discharge

46
Q

Management of calcinosis is difficult.

Medical treatment (6) and surgical (1)
Mostly unsuccessful with little supporting data, and tends to recur

A

Medical
1. Warfarin - inhibits vitamin K dependent Gla matrix protein
2. Aluminum hydroxide
3. Diltiazem
4. Probenecid
5. Sodium thiosulfate
6. IV biphosphonates - binds to calcium salt

Surgical
1. Surgical resection

47
Q

Telangiectasia are ____ that disappears and recurs with time. They are usually harmless, only cosmetic problem

SSc telangiectasia are __, shape __, size __, found on __, __, __ and __
More common in __

Treatment with __, but will recur.

If telangiectasia occurs in GI mucosa, it is called __ (__), which can bleed and lead to IDA

A

Dilated vessels (arterioles, venules, capillaries)

Matte, shaped oval or polygonal macules, size 2-7mm in diameter
Found on hands, face, lips, oral mucosa
More common in limited SSc

Treatment: laser therapy - will recur

Watermelon stomach (GAVE)

48
Q

GAVE (watermelon stomach)

A

Extensive and prominent telangiectasia of gastric mucosal surface
Resulting in acute GI bleeding, chronic IDA

Treatment: laser or argon plasma coagulation

49
Q

Bone and articular involvement in SSc demonstrated by __ (__ and __)
Resorption of __, __, ___, __, __.

Presents as __ and __, rarely as __
Hand deformities and ankylosis can be due to ____ or ____

Tendon sheaths become __ and __ mimicking __
Fibrin deposition in __ and increased thickness of __ causing tendon friction rubs.
Tendon friction rubs palpated over __, __, __
More common in __

A

Resorption of bone (acrosclerosis, osteolysis)

Arthralgia, morning stiffness, rarely as erosive arthritis

Skin thickening tethering effect or joint involvement

Tendon sheaths inflamed, fibrinous, mimicking arthritis
Fibrin deposition in tenosynovial sheath
Increased thickeness of tendon retinacula

Tendon friction rubs occur over wrists, ankles, knees
More common in diffuse SSc (50-65%)

50
Q

Muscle abnormalities in SSc

A
  1. Proximal weakness (benign myopathy)
    - Type 2 muscle fibre atrophy due to inactivity and corticosteroid use
    - No CK elevation
  2. Wax and wane
    - Interstitial fibrosis and fibre atrophy, minimal inflammatory cells
    - Mild CK elevation
    - Do not treat with steroids
  3. Inflammatory polymyositis
    - Elevated muscle enzymes
    - Treated with IST

MRCP PACES Consultations (History, Miscellaneous) (23 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions